{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    5,
    6,
    7,
    8,
    9,
    11,
    18,
    20,
    30,
    32,
    34
  ],
  "modelUsed": "gemini-3-flash",
  "confidence": 1.0,
  "amendmentDetails": {
    "studyAmendmentImpacts": [
      {
        "id": "impact_1",
        "amendmentId": "amend_7",
        "affectedSection": "Section 5.1 - Overall Study Design and Plan",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Added provisions for virtual or alternative locations for study visits due to pandemic or state of emergency."
      },
      {
        "id": "impact_2",
        "amendmentId": "amend_7",
        "affectedSection": "Section 5.3.1.1 - Study Procedures",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Modified joint assessments, pregnancy testing, and laboratory testing procedures to allow for local or home-based options."
      },
      {
        "id": "impact_3",
        "amendmentId": "amend_7",
        "affectedSection": "Section 5.5.1 - Treatments Administered",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Enabled Direct-to-Patient (DTP) shipment of study drug."
      },
      {
        "id": "impact_4",
        "amendmentId": "amend_7",
        "affectedSection": "Section 6.1.7 - Toxicity Management",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Added COVID-19 management guidance and updated ALT/AST interruption requirements."
      }
    ],
    "studyAmendmentReasons": [
      {
        "id": "reason_1",
        "amendmentId": "amend_7",
        "reasonText": "To ensure subject safety and study continuity during the COVID-19 pandemic or other states of emergency.",
        "category": "Safety",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_2",
        "amendmentId": "amend_7",
        "reasonText": "Revised text to improve consistency and readability, and/or provide clarification.",
        "category": "Administrative",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_3",
        "amendmentId": "amend_7",
        "reasonText": "Updated list of commonly used strong cytochrome 3A inducers.",
        "category": "Scientific",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_4",
        "amendmentId": "amend_7",
        "reasonText": "Updated pregnancy and product complaint reporting timelines to 24 hours per sponsor requirements.",
        "category": "Regulatory",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      }
    ],
    "studyChanges": [
      {
        "id": "change_1",
        "amendmentId": "amend_7",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "1.3",
        "afterText": "Direct-to Patient (DTP) and Coronavirus Disease â€“ 19 (COVID-19)",
        "summary": "Added new terms to the List of Abbreviations."
      },
      {
        "id": "change_2",
        "amendmentId": "amend_7",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "5.4.1",
        "beforeText": "Not specified",
        "afterText": "Subjects will have to discontinue study drug treatment immediately if they develop a gastrointestinal perforation with the exception of appendicitis or mechanical injury.",
        "summary": "Clarified discontinuation criteria for gastrointestinal perforation to align with Toxicity Management section."
      },
      {
        "id": "change_3",
        "amendmentId": "amend_7",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "6.1.6",
        "beforeText": "Not specified",
        "afterText": "24 hours from site staff awareness",
        "summary": "Defined pregnancy reporting timeline according to sponsor requirements."
      },
      {
        "id": "change_4",
        "amendmentId": "amend_7",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "5.1",
        "beforeText": "Not specified",
        "afterText": "Starting with Amendment 5 all subjects will receive open-label upadacitinib 15 mg QD, including those currently on upadacitinib 30 mg QD.",
        "summary": "Updated methodology to reflect that all subjects transition to open-label 15 mg QD."
      },
      {
        "id": "change_5",
        "amendmentId": "amend_7",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "5.3.1.1",
        "afterText": "Optional Home Healthcare Service Due to State of Emergency or Pandemic Situation like COVID-19",
        "summary": "Added new section allowing home healthcare visits if site visits are not feasible."
      }
    ],
    "summary": {
      "impactCount": 4,
      "reasonCount": 4,
      "changeCount": 5
    }
  }
}